Friday, October 5, 2018: 12:30 PM-1:45 PM
Room: S Poster Hall
Tracks: Adult ID, Investigative ID
Presentations:
Safety and Pharmacokinetic Profile of PC786, a Novel Inhibitor of Respiratory Syncytial Virus L-protein Polymerase, in a Single and Multiple-Ascending Dose Study in Healthy Volunteer and Mild Asthmatics
Lindsey Cass, PhD;
Amanda Davis, PhD;
Alison Murray, MBBCh, FRCPath;
Kathy Woodward, RNG, PgDip;
Kazuhiro Ito, PhD;
Pete Strong, PhD;
Garth Rapeport, MD, PhD
A Pooled Analysis of Patients with Wound Infections in the Phase 3 REVIVE Trials: Randomized, Double-blind Studies to EValuate the Safety and Efficacy of Iclaprim Versus Vancomycin for trEatment of Acute Bacterial Skin and Skin Structure Infections
David Huang, MD, PhD, FIDSA, FACP;
G. Ralph Corey, MD;
Thomas L. Holland, MD;
Thomas P. Lodise Jr., PharmD, PhD;
William O'Rirodan, MD;
Mark Wilcox, MD;
Thomas M. File Jr., MD;
Matthew Dryden, MD, FRCPath, FRCPS;
Antoni Torres, MD, PhD, FERS;
Barbara Balser, DVM;
Eve Desplats, BS
Results for the supplemental microbiological modified intent-to-treat (SmMITT) population of the RESTORE-IMI 1 trial of imipenem/cilastatin/relebactam (IMI/REL) versus imipenem/cilastatin plus colistin (IMI+CST) in patients (pts) with imipenem-nonsusceptible (NS) bacterial infections
Keith Kaye, MD, MPH;
Thomas File, MD;
Helen W. Boucher, MD, FIDSA;
Michelle Brown, RN;
Angela Aggrey, PhD;
Ireen Khan, MD;
Hee-Koung Joeng, PhD;
Robert Tipping, MS;
Jiejun Du, PhD;
Katherine Young, MS;
Joan Butterton, MD;
Nicholas A. Kartsonis, MD;
Amanda Paschke, MD, MSCE
Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data
Michael Trang, Pharm.D.;
Justin C. Bader, Pharm.D., MBA;
Eric A. Ople, BSc;
William G. Kramer, Ph.D.;
Michael R. Hodges, MBBS, BSc;
Sujata M. Bhavnani, Pharm.D., M.S.;
Christopher M. Rubino, Pharm.D.
In vitro activity of plazomicin, a next-generation aminoglycoside, against carbapenemase-producing Klebsiella pneumoniae
Michael R. Jacobs, MD PhD;
Caryn E. Good, MA/MPH;
Ayman M. Abdelhamed, MD PhD;
Daniel D. Rhoads, MD;
Kristine M. Hujer, BS;
Andrea M. Hujer, BS;
Susan D. Rudin, BS;
T. Nicholas Domitrovic, MS;
Lynn Connolly, MD, PhD;
Kevin M. Krause, MBA;
Sandra S. Richter, MD;
David Van Duin, MD, PhD;
Barry N. Kreiswirth, PhD;
Robert A. Bonomo, MD
Therapeutic Effects of Baloxavir Marboxil against Influenza A Virus Infection in Ferrets
Mitsutaka Kitano, Ph.D.;
Takanobu Matsuzaki, MS;
Ryoko Oka, BS;
Kaoru Baba, AS;
Takahiro Noda, AS;
Yuki Yoshida, MS;
Kenji Sato, MS;
Ryu Yoshida, Ph. D.;
Akihiko Sato, Ph. D.;
Hiroshi Kamimori, Ph. D.;
Takao Shishido, PhD;
Akira Naito, Ph. D.
In vitro activity of cefiderocol (S-649266), a siderophore cephalosporin, against Enterobacteriaceae with defined extended-spectrum β-lactamases and carbapenemases
Michael R. Jacobs, MD PhD;
Ayman M. Abdelhamed, MD PhD;
Caryn E. Good, MA/MPH;
Daniel D. Rhoads, MD;
Kristine M. Hujer, BS;
Andrea M. Hujer, BS;
T. Nicholas Domitrovic, MS;
Susan D. Rudin, BS;
Sandra S. Richter, MD;
David Van Duin, MD, PhD;
Barry N. Kreiswirth, PhD;
Robert A. Bonomo, MD
Clinical Cure in Secondary Efficacy Populations in Patients with Complicated Urinary Tract Infection Treated with ZTI-01 (fosfomycin for injection): Findings from the ZEUS Trial
Keith Kaye, MD, MPH;
Louis B. Rice, MD, FIDSA;
Viktor Stus, MD, PhD;
Olexsiy Sagan, MD;
Elena Fedosiuk, MD;
Anita Das, PhD;
David Skarinksy, BS;
Paul B. Eckburg, M.D.;
Kristina Manvelian, MS;
Evelyn J. Ellis-Grosse, PhD
Cefepime/VNRX-5133 Broad-Spectrum Activity is Maintained against Emerging KPC- and PDC-Variants in Multidrug Resistant K. pneumoniae and P. aeruginosa.
Denis Daigle, Ph.D.;
Jodie Hamrick, B.Sc.;
Cassandra Chatwin, B.Sc.;
Natalia Kurepina, Ph.D.;
Barry N. Kreiswirth, PhD;
Ryan K. Shields, PharmD;
Antonio Oliver, PhD;
Cornelius J. Clancy, M.D.;
Minh-Hong Nguyen, MD;
Daniel Pevear, Ph.D.;
Luigi Xerri, Ph.D.
Activity of Ceftriaxone-Sulbactam-EDTA Against Multi-Drug Resistant A. baumannii, P. aeruginosa and Enterobacteriaceae Isolates (WHO Critical Priority Pathogens) Collected from Various Hospitals in India
Ruchi Girotra, DNB (Microbiology);
Anurag Pyasi, PhD;
Manu Chaudhary, PhD;
N. S. Patil, MD (Microbiology);
Mohd Amin Mir, MS, MSc, PGDPM;
Saransh Chaudhary, BSc (Hons);
Pankaj Mandale, MBBS, MPH
CME Credits: Maximum of 0.00 hours of
AMA PRA Category 1 Credit™
